H.C. Wainwright Raises Alpha Tau Medical Price Target to $15

H.C. Wainwright has raised its price target for Alpha Tau Medical to $15 per share, based on the company's new trial data. Analysts note that the data supports the company's growth potential. Alpha Tau Medical is a biotechnology firm focused on cancer treatment. Its alpha radiation therapy has shown promising results in clinical trials, attracting investor interest. The raised target indicates a potential above the company's current market value. Analysts believe the trial data could help the company secure further approvals in the future. Alpha Tau Medical shares are being closely monitored by investors following this news. Future developments may impact the stock's performance. This is not investment advice.